5 terminated, 4 completed, 3 withdrawn, 1 unknown. 13 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Terminated 5, Completed 4, Withdrawn 3, Unknown 1 |
| Phase 2 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 3 | Withdrawn | APR Applied Pharma Research s.a. | 2021-12-15 | 2026-05-14 | |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | Hospital Universitario San Ignacio | 100 | 2020-09-30 | 2021-08-10 |
| TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet, Placebo - Healthcare Workers, COVID-19 | Phase 3 | Terminated | Hospital Italiano de Buenos Aires | 1378 | 2020-07-31 | 2025-09-09 |
| Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Dornase Alfa Inhalation Solution - SARS-CoV 2, ARDS | Phase 3 | Completed | University of Missouri-Columbia | 30 | 2020-06-19 | 2021-04-14 |
| Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection Hydroxychloroquine, Vitamin D - COVID-19, SARS-CoV 2 | Phase 3 | Terminated | Sanford Health | 1 | 2020-05-14 | 2021-12-10 |
| Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus? Hydroxychloroquine, Placebo oral tablet - Pre-Exposure Prophylaxis, Coronavirus | Phase 3 | Terminated | Megan Landes | 13 | 2020-04-30 | 2021-04-29 |
| Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin - Coronavirus Infections, SARS-CoV 2 | Phase 3 | Withdrawn | Apsen Farmaceutica S.A. | 2020-04-30 | 2026-09-08 | |
| Test and Treat COVID 65plus+ Hydroxychloroquine, Placebo - SARS-CoV 2, COVID-19 | Phase 2 / Phase 3 | Withdrawn | University Hospital Tuebingen | 2020-04-21 | 2021-01-15 | |
| Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers. Melatonin 2mg, Placebo oral tablet - Covid19, SARS-CoV 2 | Phase 2 / Phase 3 | Completed | Instituto de Investigación Hospital Universitario La Paz | 450 | 2020-04-20 | 2021-11-23 |
| Efficacy of Tocilizumab on Patients With COVID-19 Tocilizumab, Placebos - SARS-CoV 2 | Phase 3 | Completed | Massachusetts General Hospital | 243 | 2020-04-20 | 2021-07-27 |
| Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19 Chloroquine, Hydroxychloroquine, standard care - COVID, COVID-19 | Phase 3 | Completed | Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva | 142 | 2020-04-16 | 2021-05-12 |
| Will Hydroxychloroquine Impede or Prevent COVID-19 Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet - COVID-19, Coronavirus | Phase 3 | Terminated | Henry Ford Health System | 624 | 2020-04-07 | 2022-06-21 |
COVID-19 (8) · Coronavirus Infections (6) · Acute Lung Injury (2) · Dyspnea (2) · Respiratory Distress Syndrome (2) · Severe Acute Respiratory Syndrome (2) · Lung Diseases (1) · Pneumonia, Viral (1)
Respiratory Tract Diseases (11) · Lung Diseases (10) · Coronaviridae Infections (9) · Infections (9) · Nidovirales Infections (9) · RNA Virus Infections (9) · Respiratory Tract Infections (9) · Virus Diseases (9) · Pneumonia (8) · Pneumonia, Viral (7) · Coronavirus Infections (3) · Lung Injury (2) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2) · Signs and Symptoms (2)
Hydroxychloroquine (5) · aviptadil (2) · Azithromycin (1) · Chloroquine (1) · Emtricitabine (1) · Melatonin (1) · Standard of Care (1) · Vitamin D (1) · dornase alfa (1) · tenofovir alafenamide (1) · tocilizumab (1)
APR Applied Pharma Research s.a. (2) · Apsen Farmaceutica S.A. (1) · Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva (1) · Henry Ford Health System (1) · Hospital Italiano de Buenos Aires (1) · Hospital Universitario San Ignacio (1) · Instituto de Investigación Hospital Universitario La Paz (1) · Massachusetts General Hospital (1) · Megan Landes (1) · Sanford Health (1) · University Hospital Tuebingen (1) · University of Missouri-Columbia (1)
United States (5) · Brazil (2) · Argentina (1) · Canada (1) · Colombia (1) · Germany (1) · Spain (1)
Jonathan C Javitt, MD, MPH (2) · Adam Schrum, PhD (1) · Alberto M Borobia, MD, PhD (1) · Antonio J Carcas (1) · Dee Dee Wang, MD (1) · Elvira Zini, MD (1) · Esteban Nannini, MD (1) · Fernando Riera, MD (1) · Gonzalo Corral, MD (1) · Gustavo Costilla Campero, MD (1) · Gustavo D Lopardo, MD (1) · John H Stone, MD (1)
PMID 32650818, PMID 33085857, PMID 33907251, PMID 34745093, PMID 36160152